X
ACAD icon

Xponance’s Acadia Pharmaceuticals ACAD Stock Holding History

Xponance’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$326K Buy
12,897
+1,027
+9% +$22.6K ﹤0.01% 1354
2026
Q1 		$264K Buy
11,870
+877
+8% +$21K ﹤0.01% 1345
2025
Q4 		$294K Buy
10,993
+59
+0.5% +$1.41K ﹤0.01% 1193
2025
Q3 		$233K Buy
10,934
+24
+0.2% +$568 ﹤0.01% 1283
2025
Q2 		$235K Sell
10,910
-675
-6% -$12.5K ﹤0.01% 1249
2025
Q1 		$192K Buy
11,585
+1,434
+14% +$26.1K ﹤0.01% 1280
2024
Q4 		$186K Buy
+10,151
New +$164K ﹤0.01% 1304
2024
Q1 		– Sell
-9,552
Closed -$299K – 1312
2023
Q4 		$299K Buy
+9,552
New +$228K ﹤0.01% 1065
2021
Q2 		– Sell
-11,827
Closed -$305K – 1248
2021
Q1 		$305K Buy
11,827
+216
+2% +$9.51K 0.01% 958
2020
Q4 		$621K Buy
11,611
+44
+0.4% +$2.18K 0.01% 647
2020
Q3 		$477K Buy
11,567
+338
+3% +$14.6K 0.01% 662
2020
Q2 		$544K Buy
+11,229
New +$539K 0.01% 562

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Xponance's ACAD Position: Q2 2026 in Review

Xponance increased its Acadia Pharmaceuticals (ACAD) stake by 8.7% in Q2 2026, buying an estimated $22.6K and bringing the position to 12,897 shares worth $326K. The position accounts for ﹤0.01% of the portfolio, ranked #1354.

Xponance first reported a position in ACAD in Q2 2020 and has held it in 12 quarters since. The position peaked at $621K in Q4 2020. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Xponance held 12,897 shares of Acadia Pharmaceuticals worth $326K as of Q2 2026.
  • Xponance bought 1,027 Acadia Pharmaceuticals shares in Q2 2026, an estimated $22.6K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1354 holding.
  • Xponance first reported a position in Acadia Pharmaceuticals in Q2 2020 and has held it in 12 quarters since.
  • Xponance's Acadia Pharmaceuticals position peaked at $621K in Q4 2020.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.